Tests CD19/70 CAR-T cell therapy in people with B cell cancers
Tests CD19/70 CAR-T cells in people with CD19 or CD70 B cell cancers.
Plain-language title generated from the registry record
Registry title: CD19/70 Bi-specific CAR-T Cell Therapy
Key facts
- Where
- Shenzhen, ChinaSee the site
- Phase
- Phase 1/2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with B cell cancers whose cancer cells carry CD19 or CD70. They get a CAR-T cell therapy aimed at both markers.
- Age
- From 6 months to 75 years.
- Sex
- All sexes can join.
- Disease stage
- B cell malignancy with CD19 or CD70 on the surface of the cancer cells. KPS score over 80 points and expected survival of more than 1 month.
- Earlier treatment
- People whose earlier CD19 and CD70 CAR-T treatment failed cannot join. No systemic steroid treatment within a week of the treatment.
- Biomarker or test result
- CD19 or CD70 on the surface of the malignant B cells.
Main reasons for not taking part
- Another active disease that makes it hard to judge the response
- Uncontrolled bacterial, fungal or viral infection
- Living with HIV
- Active HBV or HCV infection
- Pregnant or nursing mothers
Read by machine on 9 November 2026.
Where in China
- Shenzhen Geno-immune Medical InstituteShenzhen, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Shenzhen Geno-Immune Medical Institute
- Trial code
- NCT05436496
- Record updated
- 2 November 2026
- Original description
The purpose of this study is to assess the feasibility, safety and efficacy of CD19/70 bi-specific CAR-T cell therapy in patients with CD19 and/or CD70 positive B cell malignancies. Another goal of the study is to learn more about the safety and function of the anti-CD19/70 bi-specific CAR-T cells and their persistency in patients.Read full original descriptionShow less
CD19/70 Bi-specific CAR-T Cells Targeting B Cell Malignancies
The purpose of this study is to assess the feasibility, safety and efficacy of CD19/70 bi-specific CAR-T cell therapy in patients with CD19 and/or CD70 positive B cell malignancies. Another goal of the study is to learn more about the safety and function of the anti-CD19/70 bi-specific CAR-T cells and their persistency in patients.
Inclusion: age older than 6 months; malignant B cell surface expression of CD19 or CD70 molecules; the KPS score over 80 points, and survival time is more than 1 month; greater than Hgb 80 g/L; no contraindications to blood cell collection.
Exclusion: under systemic steroid treatment within a week of the treatment; prior failed CD19 and CD70 CAR-T treatment; accompanied with other active diseases and difficult to assess patient response; bacterial, fungal, or viral infection, unable to control; living with HIV; active HBV or HCV infection; pregnant and nursing mothers.